Parathyroidectomy for adults with primary hyperparathyroidism

Area of Science:

• Endocrinology
• Surgical Oncology
• Evidence-Based Medicine

Background:

• Primary hyperparathyroidism (PHPT) is characterized by excessive parathyroid hormone production, often asymptomatic but can lead to severe health issues.
• Surgical removal of parathyroid tissue (parathyroidectomy) is the primary treatment for symptomatic PHPT, yet its benefits for asymptomatic or mild cases are not well-defined.

Approach:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) comparing parathyroidectomy to observation or medical therapy.
• Searched major databases (CENTRAL, MEDLINE, etc.) up to November 2021, including RCTs meeting selection criteria.
• Assessed primary outcomes (cure, morbidity, adverse events) and secondary outcomes (mortality, quality of life) using GRADE methodology.

Key Points:

• Parathyroidectomy likely results in a high cure rate for PHPT (99.4%) compared to observation or medical therapy.
• Evidence regarding parathyroidectomy's effect on bone mineral density, cardiovascular function, serious adverse events, and mortality remains very uncertain.
• No significant impact was observed on hospitalizations for hypercalcemia, with inconsistent effects on quality of life.

Conclusions:

• Parathyroidectomy significantly increases PHPT cure rates but has uncertain short-term effects on other health parameters.
• High uncertainty in current evidence limits clinical applicability, especially for asymptomatic PHPT.
• Large-scale, multi-ethnic, long-term RCTs are crucial to determine definitive benefits and risks of parathyroidectomy versus non-surgical options.